ReviewViruses2016
Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.
Review in Viruses, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study to Evaluate Immunogenicity and Safety in Subjects With Evidence of Prior Immunity to SARS-CoV-2 of a Single Intramuscular or Intranasal Dose of the Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine
Phase II/III Parallel, Double-blind, Non-inferiority Study With Active Control, to Evaluate the Immunogenicity and Safety of a Booster Immunization Scheme With a Single Intramuscular Dose of the Recombinant Vaccine Against SARS-CoV-2
Who cites it
76 citing papers in PubMed, 140 citations in OpenAlex.
- Terminal V5 Tagging of All Four Newcastle Disease Virus Structural Proteins Is Compatible with Particle Formation in Sf9 Cells.International journal of molecular sciences · 2026Article
- A single-dose chimeric Newcastle disease virus (NDV)/chikungunya virus (CHIKV) is an effective CHIKV vaccine candidate.Journal of virology · 2026Article
- Safety and Efficacy of a Recombinant Newcastle Disease Virus Expressing Cecropin AD for Diarrhea Reduction and Intestinal Health Improvement in Domestic Pigeons.Animals : an open access journal from MDPI · 2026Article
- Development of a recombinant chimeric Newcastle disease virus-vectored vaccine conferring single-dose, triple protection against genotype VII NDV, IBDV, and H9N2 AIV.Poultry science · 2026Article
- Genotype IX Newcastle disease virus isolated from wild birds is attenuated by hemagglutinin-neuraminidase mutation.Journal of virology · 2026Article
- Discovery and structural characterization of newcastle disease virus mimetic peptides identified through phage display.Virus research · 2026Article
- Development of an RT-qPCR and a Next-Generation Sequencing approach to assess viral shedding of NDV-based SARS-CoV-2 variant vaccines.Microbiology spectrum · 2026Article
- An Attenuated Recombinant Newcastle Disease Virus of Genotype VII Generated by Reverse Genetics.Viruses · 2025Article
- Engineering the tumor microenvironment: oncolytic NDV to facilitate CAR-T cell therapy.Journal of translational medicine · 2025Review
- Evaluation of Apoptosis and Cytotoxicity Induction Using a Recombinant Newcastle Disease Virus Expressing Human IFN-γ in Human Prostate Cancer Cells In Vitro.Biomedicines · 2025Article
- Article
- Review
- Development of a genotype-matched Newcastle disease DNA vaccine candidate adjuvanted with IL-28b for the control of targeted velogenic strains of Newcastle disease virus in Africa.Veterinary research communications · 2024Article
- Characterizing Host microRNA: Virus Interactions ofViruses · 2024Article
- Article
- Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.Heliyon · 2024Review
- Mucosal Vaccination with a Newcastle Disease Virus-Vectored Vaccine Reduces Viral Loads in SARS-CoV-2-Infected Cynomolgus Macaques.Vaccines · 2024Article
- Use of live attenuated recombinant Newcastle disease virus carrying avian paramyxovirus 2 HN and F protein genes to enhance immune responses against species A rotavirus VP6 protein.Veterinary research · 2024Article
- A novel approach for efficient co-expression of two foreign genes based on the reverse genetic system of Newcastle disease virus.Frontiers in microbiology · 2024Article
- Safety evaluation of recombinant Newcastle disease virus expressing IBV multi-epitope chimeric live vaccine.Frontiers in microbiology · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral vaccine vectors have shown to be effective in inducing a robust immune response against the vaccine antigen. Newcastle disease virus (NDV), an avian paramyxovirus, is a promising vaccine vector against human and veterinary pathogens. Avirulent NDV strains LaSota and B1 have long track records of safety and efficacy. Therefore, use of these strains as vaccine vectors is highly safe in avian and non-avian species. NDV replicates efficiently in the respiratory track of the host and induces strong local and systemic immune responses against the foreign antigen. As a vaccine vector, NDV can accommodate foreign sequences with a good degree of stability and as a RNA virus, there is limited possibility for recombination with host cell DNA. Using NDV as a vaccine vector in humans offers several advantages over other viral vaccine vectors. NDV is safe in humans due to host range restriction and there is no pre-existing antibody to NDV in the human population. NDV is antigenically distinct from common human pathogens. NDV replicates to high titer in a cell line acceptable for human vaccine development. Therefore, NDV is an attractive vaccine vector for human pathogens for which vaccines are currently not available. NDV is also an attractive vaccine vector for animal pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.